NNNN - CIK 0001982708
The table below shows Anbio Biotechnology's cash flow statement line items across its last 4 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating cash flow | -$6.74M | $2.08M | $898.37K | $4.45M |
| Capital expenditure | - | - | - | - |
| Investing cash flow | -$4.20M | $337.10K | $1.73M | -$1.53M |
| Dividends paid | - | - | - | - |
| Stock buybacks | - | - | - | - |
| Financing cash flow | $6.95M | -$344.61K | -$42.84K |
Anbio Biotechnology reported operating cash flow of -$6.74M for fiscal year 2025. That is down 423.9% from $2.08M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |